Hoe verhoudt PNV's PS Ratio zich tot zijn concurrenten?

PNV is duur op basis van de Price-To-Sales -ratio ( 14.5 x) vergeleken met het gemiddelde van de peer ( 2.5 x).

Hoe verhoudt PNV's PS Ratio zich tot andere bedrijven in de AU Medical Equipment industrie?

PNV is duur op basis van de Price-To-Sales -ratio ( 14.5 x) vergeleken met het Australian Medical Equipment -industriegemiddelde ( 4.3 x).

Wat is PNV's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

PNV is duur op basis van de Price-To-Sales Ratio ( 14.5 x) vergeleken met de geschatte Fair Price-To-Sales Ratio ( 9.6 x).

Wat is de reële prijs van PNV als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

PNV ( A$2.16 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( A$3.03 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is minder dan 20 % hoger dan de huidige aandelenkoers.

PolyNovo (ASX:PNV) - Aandelenkoers, Nieuws & Analyse

PNV Overzicht aandelen

PolyNovo Limited ontwerpt, produceert en verkoopt biologisch afbreekbare medische hulpmiddelen in de Verenigde Staten, Australië, Nieuw-Zeeland en internationaal. Meer informatie

PNV fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	3/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 28.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 38.4% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

PolyNovo Limited Concurrenten

Nanosonics

ASX:NAN

AU$985.9m

Ansell

ASX:ANN

AU$4.8b

SDI

ASX:SDI

AU$131.3m

Next Science

ASX:NXS

AU$39.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor PolyNovo
Historische aandelenkoersen
Huidige aandelenkoers	AU$2.16
52 Week Hoogtepunt	AU$2.78
52 Week Laag	AU$1.34
Bèta	1.72
11 maand verandering	3.35%
3 maanden verandering	-7.69%
1 Jaar Verandering	57.09%
33 jaar verandering	57.09%
5 jaar verandering	22.73%
Verandering sinds IPO	980.00%

Recent nieuws en updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Oct 10

Recent updates

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

Rendement voor aandeelhouders

	PNV	AU Medical Equipment	AU Markt
7D	8.5%	4.1%	1.5%
1Y	57.1%	13.4%	17.9%

Rendement versus industrie: PNV overtrof de Australian Medical Equipment industrie, die het afgelopen jaar een rendement 13.4 % opleverde.

Rendement versus markt: PNV overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 17.9 %.

Prijsvolatiliteit

Is PNV's price volatile compared to industry and market?
PNV volatility
PNV Average Weekly Movement	5.7%
Medical Equipment Industry Average Movement	9.0%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.2%

Stabiele aandelenkoers: PNV heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van PNV is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1998	254	Swami Raote	polynovo.com

PolyNovo Limited ontwerpt, produceert en verkoopt biologisch afbreekbare medische hulpmiddelen in de Verenigde Staten, Australië, Nieuw-Zeeland en internationaal. Het bedrijf biedt NovoSorb Biodegradable Temporising Matrix, een huidsteiger voor de regeneratie van de lederhuid wanneer deze verloren is gegaan door een uitgebreide operatie, trauma of brandwond. Het ontwikkelt ook hernia-instrumenten voor herniaherstel en oplossingen voor ventrale hernia en complexe buikwandreconstructie; NovoSorb Dermal Beta Cell, een nieuwe intracutane ectopische pancreas voor de behandeling van diabetes type 1; NovoSorb MTX voor transplantatie in één stadium bij brandwonden, chronische en chirurgische wonden; en producten voor plastische en reconstructieve hulpmiddelen.

PolyNovo Limited Samenvatting

Hoe verhouden de winst en inkomsten van PolyNovo zich tot de beurswaarde?
PNV fundamentele statistieken
Marktkapitalisatie	AU$1.49b
Inkomsten(TTM)	AU$5.26m
Inkomsten(TTM)	AU$103.23m

283.6x

Koers/Winstverhouding

14.5x

P/S-verhouding

Is PNV overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PNV resultatenrekening (TTM)
Inkomsten	AU$103.23m
Kosten van inkomsten	AU$16.41m
Brutowinst	AU$86.82m
Overige uitgaven	AU$81.56m
Inkomsten	AU$5.26m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.0076
Brutomarge	84.11%
Nettowinstmarge	5.10%
Schuld/Eigen Vermogen Verhouding	3.6%

Hoe presteerde PNV op de lange termijn?

Bekijk historische prestaties en vergelijking

PNV Overzicht aandelen

Beloningen

Risicoanalyse

PolyNovo Limited Concurrenten

ASX:NAN

AU$985.9m

ASX:ANN

AU$4.8b

ASX:SDI

AU$131.3m

ASX:NXS

AU$39.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 21% undervalued

Recent updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 21% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Now 20% undervalued

Price target increased by 7.0% to AU$2.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 24% undervalued

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 21% undervalued

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations